Anticoagulation in type 2 myocardial infarctions: Lessons learned from the rivaroxaban in type 2 myocardial infarctions feasibility trial

Pishoy Gouda, Robert Kay,Arjun Gupta,Tiffany Yuen,Malik Elharram, Jean-Bernard Breau, Syed Gilani, Darren Lau,Janek Senaratne, Albert KY. Tsui,Ross Tsuyuki,Michelle Graham

Contemporary Clinical Trials Communications（2023）

引用 0|浏览0

暂无评分

摘要

Patients with a T2MI are challenging to recruit into clinical trials involving oral anticoagulation. Future studies should account for only ∼1 in every 20 screened individuals being a candidate for study recruitment.

查看译文

关键词

anticoagulation,myocardial infarctions,rivaroxaban

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要